Quoin (QNRX) Q2 Loss Beats Estimates
Quoin Pharmaceuticals (NASDAQ:QNRX), a clinical-stage biotech focused on rare dermatological diseases, announced its second quarter 2025 results on August 7, 2025. The highlight was a net loss per American Depositary Share (ADS) of $(6.28) (GAAP), which beat the consensus GAAP estimate of -6.82. The company reported zero revenue, in line with expectations. Operating expenses jumped sharply as it increased investment in its lead asset, QRX003, for Netherton Syndrome. The quarter saw multiple regulatory wins that supported clinical progress, but the cash position declined as spending increased. Overall, the period was defined by progress in clinical and regulatory milestones, but also a rising cash burn and the ongoing absence of product revenue.
Source: Analyst estimates for the quarter provided by FactSet.
Quoin Pharmaceuticals specializes in developing therapies for rare and orphan diseases, with a main focus on dermatological conditions that have few or no approved treatments. Its primary pipeline asset is QRX003, an investigational topical lotion targeting Netherton Syndrome, a severe genetic skin disorder with unmet medical needs. The company's approach is typical for the biotech space, targeting high-impact rare disease markets with regulatory incentive programs, such as orphan drug status.
Source Fool.com
